Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive malignancy with a median survival of 12-14 months. To identify pathogenetic relevant genomic aberrations and molecular targets for therapy, we analyzed skin biopsy samples obtained from 14 patients using high-resolution array-based comparative genomic hybridization and immunostaining. Losses of chromosomes 9, 12, 13, and 15 were detected most frequently. Loss of the CDKN1B locus was the most common finding and was detected in 64% of tumors. In all but one case, the dose-dependent haploinsufficient cell-cycle inhibitor p27 KIP1 , encoded by CDKN1B, was weakly expressed in the nuclei of tumor cells. Losses of the CDKN2A-ARF-CDKN2B locus occurred in 50% of patients, and in one case a distinct biallelic loss was identified. The cell-cycle inhibitor p16 INK4a , which is encoded by CDKN2A, was not expressed in tumor cells, suggesting a complete loss of function. Loss of chromosome 13, including the RB1 gene, was observed in 43% of tumors. These results imply that alterations of the cell-cycle checkpoint controlling proteins p27 KIP1 , p16 INK4a , and RB1 may exert a profound effect in malignant transformation in BPDCN. The elucidation of the affected pathways may guide the development of new treatments specifically designed for this aggressive disease entity. These authors contributed equally to this work. Abbreviations: BPDCN, blastic plasmacytoid dendritic cell neoplasm; CGH, comparative genomic hybridization Petrella T, Dalac S, Maynadié M et al. (1999) CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Franc¸ais d 0 Etude des Lymphomes Cutanés (GFELC). Am J Surg Pathol 23:137-46 Reichard KK, Burks EJ, Foucar MK et al. (2005) CD4(+) CD56(+) lineagenegative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol 29:1274-83 Sherr C, Roberts JM (2004) Living with or without cyclins and cyclindependent kinases. Genes Dev 18:2699-711
INTRODUCTION
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignant proliferation derived from precursors of plasmacytoid dendritic cells. Clinically, patients usually present with reddish-brown (''bruise-like''), asymptomatic skin plaques and tumors, often followed by bone marrow, lymph node, and blood involvement. Although most cases show an initial response to multiagent chemotherapy, relapses are frequent and the clinical course is aggressive with a median survival of 12-14 months (Facchetti et al., 2008) .
Genetic aberrations have only been studied in a limited number of cases. Using techniques such as karyotyping, fluorescence in situ hybridization, or low-resolution comparative genomic hybridization (CGH), chromosomal abnormalities have been detected in 70% of cases. In these studies, alterations of chromosome regions 5q, 6q, 9, 12p, 13q , and 15q were most commonly found (Petrella et al., 1999; Leroux et al., 2002; Mao et al., 2003; Reichard et al., 2005) . A combined array-CGH and gene-expression study of five cases showed recurrent deletions of chromosomal regions 4q34, 9, and 13q12-q31. In this study, the RNA expression of the tumor suppressor genes RB1 and LATS2 was decreased, whereas the expression of oncogenes HES6, RUNX2, and FLT3 was increased (Dijkman et al., 2007) . Recently, an array-CGH study analyzed nine blood or lymph node samples of BPDCN and reported deletions of the tumor suppressor genes RB1, CDKN1B, CDKN2A, and TP53 (Jardin et al., 2009) . The authors suggested that the loss of these genes may represent crucial oncogenetic events in BPDCN, because they may alter the G1/S transition.
Although studies by Dijkman et al. and Jardin et al. nicely demonstrated the power of array CGH to characterize genomic alterations in BPDCN, genetic data for this disease still remain limited and variable. In this study, we significantly extend the genetic data of BPDCN in a series of 14 patients and confirm the central genetic results on the protein level. Owing to the aggressive clinical course and the currently insufficient treatment options, we discuss possible implications of the revealed alterations for new therapeutic strategies.
RESULTS AND DISCUSSION

Patients and recurrent genomic changes
All 14 patients presented with typical clinical and histological features (1 woman, 13 men; aged 38-89 years; mean age 68 years; Table 1 ). Only pretreatment skin biopsy samples were analyzed using genome-wide, high-resolution array CGH. Chromosomal aberrations, predominantly losses, were observed in all analyzed samples. Losses on chromosomes 12 (8 cases), 9 (7 cases), 13 (6 cases), and 15 (5 cases) were detected most frequently ( Figure 1 , Table 2 ). Analysis of available follow-up data did not show any correlation between specific sets of genetic aberrations or p27 KIP1 and p16 INK4a immunohistochemical staining patterns and prognosis (Table 1) . A complete summary of genomic aberrations of each case, including ideograms, start and stop positions of deleted/duplicated regions, and affected genes is included in Supplementary Table S1 .
Loss of chromosome region 12p13 and the weak expression of p27 KIP1
Loss of the chromosome region 12p13 was the most frequent finding (Figure 2a ). The common deleted region had a size of only 1.6 Mb and includes the CDKN1B gene, which encodes the p27 KIP1 protein. To further confirm the involvement of this gene in oncogenesis, we performed immunostaining and found in all but 1 of our 14 cases, a weak expression of p27 KIP1 in the nuclei of tumor cells ( Figure 2c ). Between these weakly p27 KIP1 -expressing cells, few scattered tumor cells with a strong nuclear expression were constantly found. The monoallelic losses of CDKN1B in 64% of cases and the weak nuclear expression of p27 KIP1 in the great majority of tumor cells indicate the presence of an unaltered second allele.
The p27 KIP1 protein is an important dose-dependent haploinsufficient tumor suppressor and has complex functions in cell-cycle regulation (Chu et al., 2008) . High levels of p27 KIP1 arrest the cell cycle by inhibiting cyclin E-dependent kinases, but low levels of p27 KIP1 drive the cell cycle by stabilizing cyclin D-dependent kinases (Sherr and Roberts, 2004). Inactivation of both p27 KIP1 alleles is rare in tumors, possibly because it may not provide sufficient advantage over the heterozygous state (Fero et al., 1998) . In most human malignancies, including lung, breast, ovarial, prostatic, gastric, and colon cancer, deletions and mutations of CDKN1B are rare, but downregulation of p27 KIP1 due to other mechanisms is common and correlates strongly with high tumor grade and poor prognosis (Chu et al., 2008) . The frequent loss of the CDKN1B gene in BPDCN, and the constantly weak expression of its gene product p27 KIP1 , may indicate a profound effect on tumorigenesis, and may partly explain the aggressiveness of this disease.
The commonly deleted 12p13 region also harbors the ETV6 gene, which acts as a transcriptional repressor. In hematological malignancies, alterations of both ETV6 alleles are frequently observed; one allele is involved in a translocation resulting in the formation of a new fusion gene, whereas the second allele is lost (Bohlander, 2005) . These concomitant translocations and deletions led to the suggestion that ETV6 may act as a tumor suppressor, but the oncogenetic relevance seems to result more from the formation of fusion genes than from deletions (Bohlander, 2005) . However, translocations involving ETV6 have not yet been reported by karyotyping of BPDCN (Petrella et al., 1999; Leroux et al., 2002; Reichard et al., 2005) , and the relevance of the ETV6 loss alone is at present unclear.
Loss of chromosome 9 and no expression of p16 INK4a
Chromosome 9 was the second most commonly affected in our series. Interestingly, in one case, we found a small biallelic deletion of only 500 kb (Figure 2b ), harboring the CDKN2A-ARF-CDKN2B locus, which encodes the two inhibitors of cyclin D-dependent kinases, p15 INK4b and p16 INK4a , and the unrelated ARF protein. In all of our cases, immunostaining showed that p16 INK4a was indeed not expressed in tumor cells ( Figure 2d ). observed losses of the CDKN2A-ARF-CDKN2B locus, other mechanisms such as mutations or epigenetic modifications may affect the undeleted p16 INK4a alleles. Gene products of the CDKN2A-ARF-CDKN2B locus fulfill the classical Knudson criteria for tumor suppression (''2-hit'' model) and participate in major tumor suppressor networks that are disabled in human cancer. The p16 INK4a and p15 INK4b proteins both arrest the cell cycle by inhibiting the cyclin D-dependent-kinases-mediated phosphorylation of RB1 (Kim and Sharpless, 2006) . ARF inhibits the degradation of the p53 protein (Kim and Sharpless, 2006) . Losses of these proteins in BPDCN harmfully deregulate both the RB1 and p53 pathways, indicating a critical involvement in the pathogenesis of this tumor entity.
Although losses of the CDKN2A-ARF-CDKN2B locus were also reported by Jardin et al., we additionally found frequent losses (X50%) in chromosomal regions 9p21.1, 9p13.3, and 9q34.2. This suggests that other regions and their respective genes on chromosome 9 may be involved in BPDCN pathogenesis.
Losses of chromosome 13 and RB1
We observed chromosome 13 deletions in 43% of tumors, which involved large parts of the chromosome and several tumor suppressor genes. Among those, the RB1 gene is most prominent and arrests the cell cycle by repressing the transcription of genes, the products of which are required for DNA synthesis. Cyclin D-dependent kinases, which are possibly hyperactive because of losses of their inhibitors p16 INK4a Losses on chromosomes 5q, 9, 12, 13, and 15 are most common Our results significantly extend the current knowledge regarding genetic changes in BPDCN. The three largest previous studies altogether comprised data on 27 patients (Leroux et al., 2002; Dijkman et al., 2007; Jardin et al., 2009) . Together with the 14 new cases described in this study, a relatively homogeneous pattern of common alterations in this tumor entity emerges. Losses of the common deleted region on chromosomes 9, 12, and 15 were detected in our patients and in the 3 studies in B50, 60, and 30% of cases, respectively. Losses of chromosome 13 and 5q were found in our patients in a lower percentage than in the pooled data set (43 vs 73% and 21 vs 48%, respectively). Other genomic aberrations such as losses at 6q (Leroux et al., 2002) , 4q (Dijkman et al., 2007) , or 17p (Jardin et al., 2009) , were found inconsistently in the three studies, and were also uncommon in our patients.
Conclusions and possible therapeutic implications
Our data are in agreement with previous notions by Jardin et al. that the most frequently observed deletions in the BPDCN tumor genomes most likely affect the G1/S transition. The alteration of the important cell-cycle regulating genes, namely CDKN1B, CDKN2A, ARF, CDKN2B, and RB1, may contribute to overactive cell-cycle kinases, which is often associated with aberrant division and uncontrolled proliferation of cancer cells.
The elucidation of the affected pathways in this disease may guide the development of new treatment options, specifically designed for this tumor entity. For example, in this study, we demonstrate the downregulation of p27 KIP1 , which likely destabilizes cell-cycle control. Restoration of normal p27 KIP1 levels may represent an efficient treatment option and could possibly be achieved by treatment with the mammalian target of rapamycin inhibitors (Chu et al., 2008; Meric-Bernstam and Gonzalez-Angulo, 2009 ). Inhibitors of mammalian target of rapamycin induce cell-cycle arrests in various cell systems by inactivating cyclin D-dependent kinases, which are believed to result from the downregulation of D-type cyclins and accumulation of p27 KIP1 . Moreover, the downregulation of D-type cyclins may also reduce the negative impact of p16 INK4a and p15 INK4b losses on the cell cycle. Clinical trials using mammalian target of rapamycin inhibitors have already shown promising results and clinical benefits in several cancer types, including lymphoma. On the basis of the genetic and immunostaining results, it seems possible that mammalian target of rapamycin inhibitors may be effective in BPDCN, and it seems worth evaluating their efficacy in preclinical and clinical settings.
MATERIALS AND METHODS
Tumor samples and immunophenotyping
The study was approved by the institutional ethics committee and was conducted according to the Declaration of Helsinki. The tumor In addition to the CDKN2A-ARF-CDKN2B locus, losses on chromosome 9 included large parts of the chromosome and several additional candidate genes possible involved in the pathogenesis of BPDCN.
2 Candidate genes are not mentioned, because losses included large parts of chromosomes and hundreds of genes. For all cases, a list of genomic aberrations including start and stop position, cytogenetic bands, and fluorescence log2 ratio are included in Supplementary Table S1. www.jidonline.org 1155 samples were formalin-fixed, paraffin-embedded tissue archival specimens (12 cases) or flash-frozen tissues (2 cases). The diagnosis of BPDCN was made by two independent dermatopathologists with appropriate immunohistochemical stainings as described previously (Ascani et al., 2008; Facchetti et al., 2008) . The protein expression of p27 KIP1 and p16 INK4a was evaluated with a standard immunoperoxidase technique using appropriate antibodies (p27 KIP1 : Dako, Glostrup, Denmark; p16 INK4a : MTM, Heidelberg, Germany).
DNA extraction
For DNA extraction, 10-mm sections were cut, and only areas with a tumor cell infiltration of more than 90% were microdissected as determined by a microscopic examination of adjacent sections. DNA was purified using a QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany).
Array CGH
Samples were labeled using a Bioprime Array CGH Genomic Labeling Kit according to the manufacturer's instructions (Invitrogen, Carlsberg, CA). Briefly, 500 ng test DNA and reference DNA (Promega, Madison, WI) were differentially labeled with dCTP-Cy5 and dCTP-Cy3, respectively (GE Healthcare, Piscataway, NJ).
Genome-wide analysis of DNA copy number changes was conducted using an oligonucleotide array containing 44,000 probes with a spatial resolution of 35 kb according to the manufacturer's protocol version 6.0 (Agilent, Santa Clara, CA). Slides were scanned using Agilent's microarray scanner G2505B and analyzed using Agilent DNA Analytics software 4.0.76 (statistical algorithm: ADM-2; sensitivity threshold: 8.0; consecutive clone filter: 10).
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